Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:153250547" > COVID-19 in adult a...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05674naa a2201357 4500 | |
001 | oai:prod.swepub.kib.ki.se:153250547 | |
003 | SwePub | |
008 | 240701s2023 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1532505472 URI |
024 | 7 | a https://doi.org/10.3324/haematol.2022.2808472 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Marchesi, F4 aut |
245 | 1 0 | a COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) |
264 | c 2022-05-12 | |
264 | 1 | b Ferrata Storti Foundation (Haematologica),c 2023 |
520 | a Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible. | |
700 | 1 | a Salmanton-Garcia, J4 aut |
700 | 1 | a Emarah, Z4 aut |
700 | 1 | a Piukovics, K4 aut |
700 | 1 | a Nucci, M4 aut |
700 | 1 | a Lopez-Garcia, A4 aut |
700 | 1 | a Racil, Z4 aut |
700 | 1 | a Farina, F4 aut |
700 | 1 | a Popova, M4 aut |
700 | 1 | a Zompi, S4 aut |
700 | 1 | a Audisio, E4 aut |
700 | 1 | a Ledoux, MP4 aut |
700 | 1 | a Verga, L4 aut |
700 | 1 | a Weinbergerova, B4 aut |
700 | 1 | a Szotkovski, T4 aut |
700 | 1 | a Da Silva, MG4 aut |
700 | 1 | a Fracchiolla, N4 aut |
700 | 1 | a De Jonge, N4 aut |
700 | 1 | a Collins, G4 aut |
700 | 1 | a Marchetti, M4 aut |
700 | 1 | a Magliano, G4 aut |
700 | 1 | a Garcia-Vidal, C4 aut |
700 | 1 | a Biernat, MM4 aut |
700 | 1 | a Van Doesum, J4 aut |
700 | 1 | a Machado, M4 aut |
700 | 1 | a Demirkan, F4 aut |
700 | 1 | a Al-Khabori, M4 aut |
700 | 1 | a Zak, P4 aut |
700 | 1 | a Visek, B4 aut |
700 | 1 | a Stoma, I4 aut |
700 | 1 | a Mendez, GA4 aut |
700 | 1 | a Maertens, J4 aut |
700 | 1 | a Khanna, N4 aut |
700 | 1 | a Espigado, I4 aut |
700 | 1 | a Dragonetti, G4 aut |
700 | 1 | a Fianchi, L4 aut |
700 | 1 | a Del Principe, MI4 aut |
700 | 1 | a Cabirta, A4 aut |
700 | 1 | a Ormazabal-Velez, I4 aut |
700 | 1 | a Jaksic, O4 aut |
700 | 1 | a Buquicchio, C4 aut |
700 | 1 | a Bonuomo, V4 aut |
700 | 1 | a Batinic, J4 aut |
700 | 1 | a Omrani, AS4 aut |
700 | 1 | a Lamure, S4 aut |
700 | 1 | a Finizio, O4 aut |
700 | 1 | a Fernandez, N4 aut |
700 | 1 | a Falces-Romero, I4 aut |
700 | 1 | a Blennow, Ou Karolinska Institutet4 aut |
700 | 1 | a Bergantim, R4 aut |
700 | 1 | a Ali, N4 aut |
700 | 1 | a Win, S4 aut |
700 | 1 | a Van Praet, J4 aut |
700 | 1 | a Tisi, MC4 aut |
700 | 1 | a Shirinova, A4 aut |
700 | 1 | a Schonlein, M4 aut |
700 | 1 | a Prattes, J4 aut |
700 | 1 | a Piedimonte, M4 aut |
700 | 1 | a Petzer, V4 aut |
700 | 1 | a Navratil, M4 aut |
700 | 1 | a Kulasekararaj, A4 aut |
700 | 1 | a Jindra, P4 aut |
700 | 1 | a Sramek, J4 aut |
700 | 1 | a Glenthoj, A4 aut |
700 | 1 | a Fazzi, R4 aut |
700 | 1 | a De Ramon-Sanchez, C4 aut |
700 | 1 | a Cattaneo, C4 aut |
700 | 1 | a Calbacho, M4 aut |
700 | 1 | a Bahr, NC4 aut |
700 | 1 | a El-Ashwah, S4 aut |
700 | 1 | a Cordoba, R4 aut |
700 | 1 | a Hanakova, M4 aut |
700 | 1 | a Zambrotta, GPM4 aut |
700 | 1 | a Zambrotta, G4 aut |
700 | 1 | a Sciume, M4 aut |
700 | 1 | a Booth, S4 aut |
700 | 1 | a Rodrigues, RN4 aut |
700 | 1 | a Sacchi, MV4 aut |
700 | 1 | a Garcia-Pouton, N4 aut |
700 | 1 | a Martin-Gonzalez, JA4 aut |
700 | 1 | a Khostelidi, S4 aut |
700 | 1 | a Grafe, S4 aut |
700 | 1 | a Rahimli, L4 aut |
700 | 1 | a Ammatuna, E4 aut |
700 | 1 | a Busca, A4 aut |
700 | 1 | a Corradini, P4 aut |
700 | 1 | a Hoenigl, M4 aut |
700 | 1 | a Klimko, N4 aut |
700 | 1 | a Koehler, P4 aut |
700 | 1 | a Pagliuca, A4 aut |
700 | 1 | a Passamonti, F4 aut |
700 | 1 | a Cornely, OA4 aut |
700 | 1 | a Pagano, L4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Haematologicad : Ferrata Storti Foundation (Haematologica)g 108:1, s. 22-33q 108:1<22-33x 1592-8721x 0390-6078 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153250547 |
856 | 4 8 | u https://doi.org/10.3324/haematol.2022.280847 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.